P. De Simone et al.: Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial. In: Am J Transplant. 6. Aug 2012. doi:10.1111/j.1600-6143.2012.04212.x. PMID 22882750.
S. Mielke, M. Lutz, J. Schmidhuber, M. Kapp, D. Ditz, J. Ammer, H. Einsele, G. U. Grigoleit, E, Holler, D. Wolff: Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: A dual center retrospective analysis. In: Bone Marrow Transplant. Band 49, Nr. 11, November 2014, S. 1412–1418. doi:10.1038/bmt.2014.170, PMID 25089598.
B. Nashan, F. Citterio: Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation: A Critical review of the literature. In: Transplantation. 30. Aug 2012. PMID 22941182.
Š. Vítko et al.: Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. In: Transplantation. Band 78, 2004, S. 1532.73. PMID 15599319.
Š. Vítko et al.: Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. In: Am J Transplant. Band 5, 2005, S. 2521. PMID 16162203.
M. I. Lorber et al.: Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. In: Transplantation. Band 80, 2005, S. 244. PMID 16041270.
H. J. Eisen et al.: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. In: N Engl J Med. Band 349, 2003, S. 847. PMID 12944570.
B. Nashan, J. Curtis, C. Ponticelli et al.: Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. In: Transplantation. Band 78, 2004, S. 1332. PMID 15548972.
B. Nashan: The role of Certican (everolimus, rad) in the many pathways of chronic rejection. In: Transplant Proc. Band 33, 2001, S. 3215. PMID 11750380.
H. Tedesco Silva Jr et al.: Everolimus plus reduced- exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. In: Am J Transplant. Band 10, 2010, S. 1401. PMID 20455882.
J. M. Campistol et al.: Everolimus and long-term outcomes in renal transplantation. In: Transplantation. Band 92, Nr. 3 Suppl, 15. Aug 2011, S. S3–S26. PMID 21799392.
B. Nashan et al.: Review of Cytomegalovirus Infection Findings With Mammalian Target of Rapamycin Inhibitor-Based Immunosuppressive Therapy in De Novo Renal Transplant Recipients. In: Transplantation. Band 93, 2012, S. 1075–1085. PMID 22683823.
B. Nashan, F. Citterio: Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation: A Critical review of the literature. In: Transplantation. 30. Aug 2012. PMID 22941182.
L. Fischer et al.: A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation - PROTECT. In: Am J Transplant. Band 12, Nr. 7, 2012, S. 1855–1865. PMID 22494671.
P. De Simone et al.: Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial. In: Am J Transplant. 6. Aug 2012. doi:10.1111/j.1600-6143.2012.04212.x. PMID 22882750.
S. Mielke, M. Lutz, J. Schmidhuber, M. Kapp, D. Ditz, J. Ammer, H. Einsele, G. U. Grigoleit, E, Holler, D. Wolff: Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: A dual center retrospective analysis. In: Bone Marrow Transplant. Band 49, Nr. 11, November 2014, S. 1412–1418. doi:10.1038/bmt.2014.170, PMID 25089598.
